drugset / Trial / NCT00245635
Fluoxetine in Pediatric Body Dysmorphic Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This trial will study the effectiveness of the medication fluoxetine for children and adolescents ages 16 and younger with BDD who qualify.
Timeline
- Start
- 2004-11
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluoxetine | Small molecule | 10 mg | — |
| Subject | Fluoxetine | Small molecule | 80 mg | — |